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DOI 10.1186/s12864-015-1552-yRESEARCH ARTICLE Open AccessThe potential role of Alu Y in the development of
resistance to SN38 (Irinotecan) or oxaliplatin in
colorectal cancer
Xue Lin1, Jan Stenvang2, Mads Heilskov Rasmussen3, Shida Zhu4, Niels Frank Jensen2, Line S Tarpgaard5,
Guangxia Yang4, Kirstine Belling6, Claus Lindbjerg Andersen3*, Jian Li1,4,7*, Lars Bolund1,4*† and Nils Brünner2*†Abstract
Background: Irinotecan (SN38) and oxaliplatin are chemotherapeutic agents used in the treatment of colorectal
cancer. However, the frequent development of resistance to these drugs represents a considerable challenge in the
clinic. Alus as retrotransposons comprise 11% of the human genome. Genomic toxicity induced by carcinogens or
drugs can reactivate Alus by altering DNA methylation. Whether or not reactivation of Alus occurs in SN38 and
oxaliplatin resistance remains unknown.
Results: We applied reduced representation bisulfite sequencing (RRBS) to investigate the DNA methylome in SN38
or oxaliplatin resistant colorectal cancer cell line models. Moreover, we extended the RRBS analysis to tumor tissue
from 14 patients with colorectal cancer who either did or did not benefit from capecitabine + oxaliplatin treatment. For
the clinical samples, we applied a concept of ‘DNA methylation entropy’ to estimate the diversity of DNA methylation
states of the identified resistance phenotype-associated methylation loci observed in the cell line models. We identified
different loci being characteristic for the different resistant cell lines. Interestingly, 53% of the identified loci were Alu
sequences- especially the Alu Y subfamily. Furthermore, we identified an enrichment of Alu Y sequences that likely re-
sults from increased integration of new copies of Alu Y sequence in the drug-resistant cell lines. In the clinical samples,
SOX1 and other SOX gene family members were shown to display variable DNA methylation states in their gene re-
gions. The Alu Y sequences showed remarkable variation in DNA methylation states across the clinical samples.
Conclusion: Our findings imply a crucial role of Alu Y in colorectal cancer drug resistance. Our study underscores the
complexity of colorectal cancer aggravated by mobility of Alu elements and stresses the importance of personalized
strategies, using a systematic and dynamic view, for effective cancer therapy.
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Colorectal cancer is a common and often lethal disease
[1]. FOLFIRI (folinic acid, 5-fluorouracil and irinotecan)
[2], FOLFOX (folinic acid, 5-fluorouracil and oxaliplatin)
[3] and XELOX (capecitabine and oxaliplatin) [4] are
commonly used chemotherapeutic combinations used to
treat colorectal cancer. However, a considerable subpop-
ulation of patients will experience disease recurrence
due to acquired resistance to treatment. The molecular
mechanisms underlying acquired resistance to these
drugs remain elusive.
Cancer cells usually harbour numerous genomic and
epigenomic aberrations, thereby presenting high diver-
sities of genotypes and phenotypes as well as cell fate
dynamics. For somatic cells, cell fate is well defined and
stably maintained by epigenetic mechanisms. DNA methy-
lation is a long-term stable epigenetic mechanism.
Additionally, DNA methylation represses the activity
of mobile genetic elements and maintains genome
integrity.
The concept ‘eukaryotic genomes are dynamic’ has
been well accepted [5] since mobile genetic elements
were first discovered in maize [6]. One remarkable fea-
ture in the human genome is that the DNA consists of
at least 45% mobile genetic elements, including short
interspersed nuclear elements (SINEs), long interspersed
nuclear elements (LINEs) and long terminal repeats
(LTRs) [7]. LINE-1 (L1) is a predominant member of
LINEs and Alu is the largest family of SINEs in the
human genome [7]. Moreover, L1s are the only autono-
mous retrotransposable element in the human genome.
Alus are non-autonomous retrotransposable elements,
which depend on an L1 coded protein ORP2 (endo-
nuclease and reverse transcriptase) to mediate their
mobility. Alus are primate-specific sequences sharing a
typical 282-nucleotide consensus sequence and a char-
acteristic structure [8]. There are more than one million
Alu family members, constituting 11% of human DNA
[8]. The members are ubiquitously dispersed through-
out the genome but preferentially overrepresented in
GC-rich and high gene density regions [8]. It is thought
that about 75% of the total number of genes in the
genome are associated with Alus [9]. The presence of
Alu sequences is strongly correlated with multifractality
in human genome sequences [10]. Alu elements are also
associated with more than 25% of all the simple repeti-
tive sequences in primate genomes, including microsa-
tellites [11]. It is reported that Alu and L1 initiate the
spread of CpG methylation, and the length of CpG
islands is associated with the distribution of Alu and L1
retrotransposons [12]. Moreover, Alu elements are
supposed to act as global modifiers of gene expression
through changes in their own methylation state [8]. It is
estimated that there are about 80-100 active L1s and2000-3000 active Alus in the human genome per individ-
ual [13,14]. Mobilization of Alus mainly occurs during the
production of gametes or at early stages of embryo de-
velopment [5]. In contrast to germ line retrotranspo-
sition, the activity of Alus and other mobile genetic
elements in somatic cells is mostly silenced by DNA
methylation and post-transcriptional mechanisms medi-
ated by piwi-interacting RNAs, siRNAs, miRNAs and
AID/APOBEC gene family members [5,15-18]. However,
genomic toxicity induced by carcinogens or drugs can
reactivate Alus by altering DNA methylation [19]. Ac-
cordingly, Alu and L1 have been shown to display DNA
methylation alterations in colorectal cancers compared
with matched normal tissues [20,21]. Additionally, Alu
elements pose the largest transposon-based mutagenic
threat to the human genome [14]. A recent study, which
intensively sequenced 43 cancer and matched germ line
genomes, revealed that colorectal cancers and other
cancers of epithelial cell origin show activity of somatic
L1 and Alu transpositions [22].
Among Alu sequences, the Alu Y subfamily is the
youngest Alu sequence [8] with an evolutionary age
of ~15-20 million years (Mya) [23]. Even though the
copy number of Alu Y (~125,000 copies) is less than
that of Alu S (550,000 copies, at evolutionary age ~40-50
Mya [23]) and Alu J (~160,000 copies, at evolutionary
age ~55 Mya [23]), the Alu Y subfamily harbours the
largest number of functionally intact Alu core elements
that are more active than the older Alus [14,24]. Acti-
vation of Alus can have many important biological con-
sequences: Alus can reshuffle the genome, generating
transposon-mediated mutagenesis [25], inducing gen-
omic instability [26], and increasing recombination
between elements [8], thereby contributing to genetic
population diversity [8,27] as well as to heterogeneity in
tumorigenesis. Alus can also remodel the epigenome
and alter gene expression patterns by changing epigen-
etic marks of neighbouring genes at new insertion sites,
introducing ectopic promoters of transcription factor
binding sites, and generating novel alternative splicing.
Integration of Alu sequences and subsequent remodel-
ling of DNA methylation might lead to epigenetic re-
programming [28] as well as pluripotency induction and
maintenance by A-to-I RNA editing of Alu sequences
[29]. Whether Alu retrotransposition occurs during
chemotherapy with SN38 or oxaliplatin, and thereby
plays a potential role in the development of chemother-
apy resistance, remains unknown.
We hypothesized that development of drug resistance
in colorectal cancer follows a linear step-wise progres-
sive model and in the present study, we applied reduced
representation bisulfite sequencing (RRBS) assay to
analyse the DNA methylome from 3 established SN38-
resistant and 3 established oxaliplatin-resistant human
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a potential role of Alu elements, especially the Alu Y sub-
family, in the resistance to SN38 and oxaliplatin. To valid-
ate the findings from the cell line models, we extended
our RRBS analysis to 14 clinical colorectal cancer samples.
Based on the analyses of the cell lines and clinical samples,
we have attempted to delineate the influence of altered
DNA methylation on activation of retrotransposons as a
model for colorectal cancer chemotherapy resistance.
Results
Global methylome and non-CpG methylation in the cell line
models and clinical samples
We applied the QDMR software [31] with a concept of
‘DNA methylation entropy’ adopted from the ‘Shannon
entropy’ [32], to identify differentially methylated cytosines
(DMCs) by estimating variability of DNA methylation
states between all colorectal cancer cells and clinical
samples. DMCs in all samples in the context of CpG as
well as CHG and CHH (where H means A, T or C),
were identified. Unsupervised clustering using DMCs in
the context of CpG, CHG and CHH were performed
(Additional file 1: Figure S1A, 1B and 1C). The drug-
resistant cell lines clustered with their parental cell ori-
gin in the dendrogram representing the methylome
profiles. This clustering represents the phenomenon
“somatic memory” and is in accord with data from gene
expression profiles from the cell lines [30]. Thus, the
somatic memory leads to clustering of the resistant and
parental cells rather than clustering according to spe-
cific drug-resistance. Also, all cell lines merged in a big
cluster separated from the clinical samples in unsuper-
vised clustering, suggesting that the colorectal cancer
cell lines might show similar features of DNA methy-
lome, whereas sporadic clinical samples show high
diversity between individual methylomes. In the cell line
studies, analyses were performed after chemotherapy-
induced resistance while in the clinical cancers the
samples for analyses were obtained prior to any chemo-
therapy. This could also explain separation between the
cell line samples and clinical samples in the unsuper-
vised cluster analysis. An additional factor distinguish-
ing the clinical samples from the cell lines is the clinical
samples contain a mixture of cells including cancer
cells, stromal cells and endothelial cells whereas the
cell lines are much less heterogeneous.
There were a certain number of non-CpG cytosine
(CHH and CHG) methylations in all colorectal cancer
cell lines and sporadic colorectal cancer samples. Clus-
tering based on non-CpG cytosine methylation data was
largely consistent with that based on CpG cytosine
methylation data (Additional file 1: Figure S1B and 1C).
This suggests that both CpG methylation and non-CpG
methylation reflect the general somatic memory of DNAmethylation modification. From the identified DMCs, we
selected the non-CpG cytosine loci (CHH and CHG)
shared by both the cell line models and the 14 clinical
samples with a methylation level of at least 50% or
higher in every sample. There were totals of 19 and 29
cytosine loci identified, in CHG and CHH formats
respectively. Among the CHG methylated cytosine loci,
12 loci were located in gene bodies (exon, intron, pro-
moter and TSS (transcription start site)) and 7 loci in
intergenic regions. Among the CHH methylated cytosine
loci, 15 loci were located in coding genes, 1 locus in a
microRNA gene, and 13 in intergenic regions. For the
CHG and CHH loci located in intergenic regions, most
of them were in repeat sequences. For example, there
were 3 and 6 loci harbouring in Alu elements in CHG
and CHH formats, respectively. Interestingly, 2 of these
(out of 3) and 5 (out of 6), respectively, belonged to the
Alu Y subfamily. The information concerning the identi-
fied CHG and CHH methylated loci is available in the
Additional file 2: Table S1A and 1B, respectively.
Furthermore, we investigated the distribution of the
DMCs in different genomic components. The DMCs
(composed of CpG, CHH and CHG) were mainly located
in intergenic and intronic regions. Notably, even though
the majority of CpG loci harboured more frequently in in-
trons and promoters than in intergenic regions, the largest
number of DMCs in CpG context were found in inter-
genic regions (Figure 1A). Compared with the DMCs in a
CpG context, DMCs in non-CpG contexts were less fre-
quent, residing mainly in introns, intergenic regions and
promoters (Figure 1B and Figure 1C). This result suggests
that CpG DMCs contribute predominantly to the DNA
methylation difference in intergenic regions.
The cytosine loci uniquely presented in the different
drug-sensitive or drug-resistant phenotypes enrich Alu
elements
By analysing RRBS data for the colorectal cancer cell line
models, we identified the loci unique to the three parental
cell lines (cell line A (HCT-116 parental), D (HT-29 par-
ental) and G (LoVo parental)) and defined a set P, which
contains only these parental cell line loci (including the
three formats of CpG, CHG and CHH). We then identi-
fied loci unique to the three OxPt-resistant sub-lines
(cell line B (HCT-116 OxPt resistant), E (HT-29 OxPt
resistant) and H (LoVo OxPt resistant)) as uniquely
representing OxPt-resistant DNA methylation features
and defined a set O, which contains only these OxPt-
resistant sub-line loci (including the three formats of
CpG, CHG and CHH). Finally, we identified the loci
unique to the three SN38-resistant sub-lines (cell line C
(HCT-116 SN38 resistant), F (HT-29 SN38 resistant)
and I (LoVo SN38 resistant)) as uniquely representing
SN38-resistant DNA methylation features and defined a
Figure 1 The distribution of differentially methylated cytosines (DMCs) in different genomic components. A shows the distribution of total
cytosines (blue bars) and DMCs (red bars) in the context of CpG in different components of the human genome. B and C show the distribution
of total cytosines (blue bars) and DMCs (red bars) in the context of CHH and CHG in different components of the human genome, respectively.
The height of the left vertical axis indicates the number of total cytosines in the context of CpG (A), CHG (B) and CHH (C), respectively. The
height of the right vertical axis indicates the number of the DMCs in the context of CpG (A), CHG (B) and CHH (C) for the given genomic
components, respectively.
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loci (including the three formats of CpG, CHG and
CHH). The numbers of the identified loci in sets P, O
and S are shown in Figure 2A. The definitions of the dif-
ferent sets in this study are available in the Additional
file 3: Table S2. Taking the identified loci in the context
of CpG as an example, there were 505,147, 337,242 and
359,770 cytosine loci identified as uniquely representing
drug-sensitive DNA methylation features in the parental
(P), OxPt-resistant (O), and SN38-resistant (S) cell-lines
respectively.We found that sets P, O and S are highly enriched in
Alu elements, which accounted for 48.8%, 60.1% and
53.3% of all identified cytosine loci, respectively. Notably,
many identified Alu elements belong to the youngest
Alu subfamily – Alu Y – accounting for 32.1%, 35.8%
and 34.3% in the identified Alu elements in the set P, O
and S, respectively. Subsequently, we performed RRBS
analysis for the 14 clinical samples, and then selected
the cytosine loci commonly found in these clinical sam-
ples, defined as set C. We further selected the cytosine
loci by only keeping the loci that were commonly found
Figure 2 Alu Y subfamily enrichment. A: the number of selected loci in the sets P, O and S (see text). B: the percentage of the Alu Y subfamily
out of the identified Alu elements in set E. C: the percentage of Alu elements in all cytosine loci and the percentage of the Alu Y subfamily in the
identified Alu elements in either sliding windows of fixed size or extended size in RRBS in-silico simulation.
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defined a new set E, contains only the commonly shared
cytosine loci. We identified 48,944 loci in set E. Informa-
tion about these set E cytosine loci is available in the
Additional file 4: Table S3. Notably, the percentage of
Alu elements among the identified loci in set E was
53.4%, and the percentage of the Alu Y subfamily in all
identified Alu elements in the set E was increased to
46.3% (Figure 2B). Subsequently, we performed DMCs
analysis for the identified loci and found that the Alu Y
subfamily accounted for 48.4% of the identified DMCs
Alu loci.
To exclude the possibility that the enriched Alu Y
sequences came from a possible bias of the RRBS tech-
nique, we performed an in-silico simulation. We used
the same reference genome (GRCh37) that was used for
RRBS mapping as the virtual test genome, subjecting it
to MspI digestion and recovery of the resulting DNAfrom the gel selection by keeping the proper size of the
digested DNA fragments in the in-silico stimulation.
According to our experimental protocol of RRBS library
generation, there was a maximum of about 28% se-
quences from Alu repeats in the in-silico stimulation, of
which 39.5% belonged to the Alu Y subfamily. Further-
more, we compared the number of Alu Y loci in the data
set P, O, S and the number of Alu Y loci in the simulated
data set, which demonstrated that the Alu Y enrichment
in the set of P, O, S was statistically significant (Fisher’s
exact test, p-value < 2.2e-16).
In consideration of the potential variance of cutting
sections of agarose gel from the smear of the digested
genomic DNA, we applied a sliding window by moving a
fixed size selection section from the simulated smear of
the digested genomic DNA in both directions (towards
smaller selection size or bigger selection size) and we also
extended the selected section by extending additional
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size. Neither sliding the fixed size selection section nor
extending selection size showed significant variance in
the amount of Alu sequences (Figure 2C). We could not
further simulate the alignment because it is hard to esti-
mate potential DNA methylation state for the simulated
cytosines. Since Alus are repetitive sequences, align-
ment of simulated digested genomic DNA to the human
reference genome could lead to further decrease in the
proportion of Alu sequences. This is due to problems
with low mapping quality, which results from repetitive
sequences mapping to multiple locations in the human
genome reference and/or the low priority for annotation
(the priority order is exon, intron, promoter, intergenic
region, and finally, repetitive).
Moreover, we calculated the percentage of the Alu
subfamilies (Alu Y, Alu J and Alu S) in the selected Alu
elements according to the use of sliding selection win-
dow and extending selection windows with different
size in the simulations. The percentages of the Alu sub-
families were generally consistent in all simulations
(Figure 2C). We also calculated the variance in theFigure 3 A shows the percentage of loci overlapping with the simulation
subfamilies in sets P, O and S, which are not overlapping with the simulatiorange of the percentages of Alu elements and the Alu Y
subfamily in the above simulations and compared these
variances to the variance of both the percentage of Alu
elements and the Alu Y subfamily among all the RRBS
data, including all colorectal cancer cell models and
the 14 clinical colorectal cancer samples. Clearly, the
variance of the Alu Y subfamily in all the RRBS samples
was much higher than that in the simulations, which in-
dicates that bias from RRBS technology cannot explain
the observed Alu Y enrichment in the sets P, O and S.
The information of variance in all the RRBS samples and
variance in the simulations are available in Additional
file 5: Table S4.
Subsequently, we compared the identified loci in the
sets P, O and S with the loci in the RRBS simulation
(selection section window size is 40-300 bp), respectively.
We found that 54.7%, 42.4% and 42.1% loci in the sets
P, O and S overlapped with the loci in the simulation
(Figure 3A). Moreover, we identified the common loci
shared by all nine colorectal cancer cell lines and defined a
new set A. When we compared the loci in the set A, we
found that 87.7% of the loci in set A overlapped with thein sets A, P, O and S. B shows the percentage of Alu elements, and Alu
n.
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overlapping loci reflects the difference of the genomes of
the nine cell lines from the human genome reference used
in the simulation. This difference might reflect that the
colorectal cancer cell lines harbour a certain number of
genomic aberrations and these genomic aberrations could
lead to some of the difference between the sequenced
genomic loci and the loci in the simulation. Notably, set
P from the three parental cell lines showed a lower pro-
portion of overlapping loci with the simulation com-
pared with set A, suggesting set P contained more loci
related to genomic aberrations in individual cell lines
than set A. Interestingly, set P showed higher portion of
overlapping loci with the simulation than sets O or S,
suggesting that the genomes of OxPt-resistant and
SN38-resistant cell lines had larger extents of difference
from the human genome reference than the genomes of
their parental cell lines. This implies that changes in
genomic structure in drug-resistant cell lines might
occur during drug treatment. We further analysed the
constitution of the non-overlapping loci in sets P, O and
S. As in the previous analyses, a considerable amount of
Alu elements contributed to the proportion of the non-
overlapping loci in sets P, O and S. More impressively,
the percentages of Alu elements in sets O and S were in-
creased compared with that in set P. Among Alu sub-
family members, we further confirmed that the Alu Y
subfamily mainly contributed to the increased propor-
tion of Alu elements in the total non-overlapping loci in
the drug-resistant cell lines (Figure 3B). Thus, based on
our observation and analysis, we found a correlation be-
tween the drug-resistant phenotypes and the increment
of Alu Y elements.
Alu sequences can be activated and propagate into
new loci of the human genome triggered by genotoxic
stress [5,33]. Especially, Alu Y sequences are the biggest
active subfamily of Alu elements in the human genome.
The most likely explanation of our observation in the
cell lines is that Alu Y elements were reactivated and
spread their copies in the genome when triggered by
genotoxic stress of OxPt or SN38. In the RRBS library
generation, MspI digested the genomic DNA of the
drug-resistant cell line that carried many insertions of
Alus, mainly Alu Y elements. The newly inserted Alus in
the drug-resistant cell lines will change the constitution
of digested genomic fragments. When the digested gen-
omic DNA underwent gel selection, the portion of the
digested DNA that can be finally selected by the selec-
tion section window (40-300 bp) will be changed. Conse-
quently, the sequenced part of the genome in the RRBS
libraries from the parental cell lines and the drug resist-
ant cell lines will be different. Taken together, the results
from RRBS might reflect Alu Y subfamily retrotransposi-
tion in the drug-resistant cell lines.To further validate our findings, we compared RRBS
reads that can be uniquely mapped to the human repeat
sequence between the drug-resistant cell lines and their
parental cell lines. We made a linear normalization of
the RRBS data across all the cell lines by making the
total amount of mapped RRBS reads of each sample
equal. Then we extracted the reads annotated as Alu se-
quence and compared the number of the reads uniquely
mapped to Alu sequences between the drug-resistant
cell lines and their parental cell lines. In general, all
OxPt and SN38-resistant cell lines consistently show
higher number of reads from Alu Y subfamilies than that
in their parental cell line. There is only one exception.
The SN38-resistant HT-29 cell line showed almost equal
number of the reads to its parental cell line. We trans-
formed the read number into log2 format to make the
distribution of read number fit a normal distribution.
Then we performed a paired t-test, and the statistical re-
sult showed that the number of Alu Y reads in the drug-
resistant cell lines was significantly higher than that in
their matched parental cell lines (p-value = 0.0039 for
the SN38 resistant cells vs. the parental cells; p-value =
2.13 × 10−12 for the OxPt resistant cells vs. the parental
cells, respectively). Moreover, we calculated the percent-
age of the reads of Alu subfamily members (Alu Y, Alu J
and Alu S) for all the cell line samples. The percentage
of the Alu Y subfamily in the OxPt and SN38-resistant
cell lines was higher than that in the parental cell lines
(Figure 4A). The percentages of Alu J and Alu S sub-
families in all cell lines are shown in Figure 4B and
Figure 4C, respectively.
Identifying flanking sequence motif of Alu sequences
We applied WebLogo 3.3 [34] to extract flanking se-
quence (up- and down-stream 20 bp) motif from the
Alu elements shared by all the RRBS samples, including
both the cell lines and the clinical samples in our study.
We identified a symmetric sequence in both flanking
sequences of the Alu elements (Figure 5A). Further-
more, we extracted flanking sequence motifs from the
identified Alu elements in set E, which presented the Alu
elements shared by the 14 clinical samples and the united
sets of P, O and S (Figure 5B). To see whether the above
Alu elements had unique features (motif sequences differ-
ing from the other Alu elements in the human genome),
we extracted the flanking sequence motifs for all Alu se-
quences in the human genome reference (Figure 5C).
Interestingly and in general, the flanking sequence of the
Alus identified in all the RRBS samples and the Alus iden-
tified in set E both showed highly similar motif sequence
to that of all Alus in the human genome reference, which
is also consistent with the typical Alu target site duplica-
tion (TSD) sequence. Alu insertion depends on L1-coded
ORP2, and the target site sequence of ORP2 for insertion
Figure 4 The percentage of Alu subfamilies in all colorectal cancer cell lines. A shows that the OxPt and SN38-resistant cell lines consistently show
higher percentage of the Alu Y subfamily than their parental cell lines. B and C show the percentages of Alu J and Alu S subfamilies in the cell line
models, respectively.
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Figure 5 The motif of the flanking sequence of Alu elements. A shows the motif of the flanking sequence of the identified Alu elements in all
the RRBS samples; B shows the motif of the flanking sequence of the identified Alu elements in set E; C shows the motif of the flanking sequence of all
Alu elements in the human genome reference. D shows the motif of the flanking sequence of identified Alu Y subfamily in set E.
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identified Alu sequences, either in all the RRBS samples or
in set E, typically rely on L1-coded ORP2 for their inser-
tion, which is in accordance with other observations [19].
Additionally, the ranking of the first flanking sequence (on
the left flanking sequence) of the Alus in all the RRBS
samples from the top to the bottom was A, C, T and G,
according to the probability scale. Moreover, according to
the probability scale, the ranking of the first flanking se-
quence of the Alus in set E, from the top to the bottom,
was A, C, G and T. By contrast, the ranking of the first
flanking sequence of the Alus in the whole human gen-
ome was A, T, C and G. We also extracted the flanking
sequence motifs for the Alu Y subfamily in set E. The
order of ranking the first flanking sequence from the top
to the bottom was A, C, T and G, according to the prob-
ability scale (Figure 5D). These observations suggest thatthe additional Alu elements and Alu Y subfamily elements
in this study preferably locate in GC-rich region. Since
GC-rich regions are also gene-dense regions, our result
implies their activity might have an effect on gene
function.
The identified cytosine loci in Set E highlight the high
diversity of DNA methylation in SOX1 in the clinical samples
We identified 48,944 loci in set E, which were related to
a total of 5,816 genes. Thus, many genes harbour more
than one identified cytosine locus. For example, the
TSPYL2 gene harbours 90 cytosine loci, ranking first
among the identified total of 5,816 genes. This gene en-
codes a testis specific protein, Y-encoded-like 2 (TSPYL2),
which is a nucleosome assembly protein and plays a
role in chromatin remodelling to determine gene ex-
pression, cell proliferation, and terminal differentiation
Lin et al. BMC Genomics  (2015) 16:404 Page 10 of 17[35]. Notably, SOX1 harbours 35 of the identified cytosine
loci, ranking fifteenth among the 5,816 genes. In addition
to SOX1, other SOX gene members including SOX2,
SOX3, SOX4, SOX6, SOX8, SOX11, SOX14, SOX18,
SOX21 and SOX30 have been identified to harbour at least
one identified cytosine locus. Thus there was a clear en-
richment of the SOX gene family in this data set. The gene
list and the number of harboured loci are available in
Additional file 6: Table S5.
We extracted the DNA methylation information of the
14 clinical samples on the basis of the cytosine loci in
set E. Furthermore, we estimated the diversity of DNA
methylation states across the 14 clinical samples by
measuring the DNA methylation entropy using QDMR
[31]. Interestingly, many cytosine loci located in the
SOX1 gene region showed high diversity of DNA methy-
lation states across all the 14 clinical samples (Figure 6A
and B). The cytosine loci harboured in the TSPYL2 gene
and their DNA methylation level and entropy are shown
in Additional file 7: Figure S2A and B.
Identifying differentially methylated cytosines (DMCs)
commonly presenting in both the parental cell lines and
the OxPt-resistant cell lines
In addition to the analysis of the uniquely presenting loci
in the parental cell lines (set P) or in drug-resistant cell
lines (sets O and S), we extracted the loci that were com-
monly presented in the OxPt-resistant cell lines and
their parental cell lines. DNA methylation entropy ana-
lysis [31] was applied to identify the differentially meth-
ylated cytosines that presented high diversity of DNA
methylation state across all the cell line samples. There
were 1,089,634, 2,105,795 and 726,658 cytosine loci
identified as OxPt-resistant phenotype associated methy-
lation loci in the context of CpG, CHH and CHG, re-
spectively. We hypothesized that colorectal cancer cells
either from in vitro samples (the cell line models) or
from in vivo samples (the clinical samples) share com-
mon epigenetic alterations, which are epigenetic changes
responsible for the development of an OxPt-resistant
phenotype. Thus, we transferred the extracted OxPt-
resistant phenotype associated methylation loci from the
analysis of the cell line models to the clinical samples.
Because the methylomes of the patient samples repre-
sented the DNA methylation profiles prior to drug treat-
ment, we tested whether the identified ‘OxPt resistant
phenotype associated methylation loci’ in the cell line
models could classify the patients into good or poor out-
come groups correctly.
Briefly, we extracted the ‘OxPt resistant phenotype-
associated methylation loci’ from the 14 RRBS clinical
samples. Subsequently, we performed unsupervised clus-
tering analysis based on the extracted loci to see whether
the identified loci in the cell line models could group thepatients according to good or poor outcome to treat-
ment (complete response (CR) and partial response (PR)
versus no change (NC) and progressive disease (PD)).
However, we did not obtain a clearly distinguishable
grouping according to good and poor phenotypes (data
not shown).
In the next step, we performed a prediction analysis
for individual patients to see whether the identified
‘OxPt resistant phenotype associated methylation loci’
could correctly predict the outcome for each patient.
We used the DNA methylation information of the iden-
tified loci extracted from all the 14 patients as a training
data set to select key features and then build a predictor
using K-Nearest Neighbour (KNN) [36]. Then, we per-
formed a leave-one-out validation to estimate the accur-
acy of the prediction. For the ‘OxPt resistant phenotype
associated loci’ in the context of CpG, we got an accur-
acy of 35.7% for the clinical samples to be predicted as
good or poor outcome group correctly (Fisher exact test,
p-value = 0.59). The OxPt resistant phenotype associated
CHH and CHG loci showed 35.7% (p-value = 0.3) and
64.3% (p-value = 0.5804) accuracies, respectively. These
results show that it is hard to precisely predict the out-
come for individual patients simply based on the DNA
methylation state in certain regions identified by the lim-
ited number of cell line models. This suggests that DNA
methylomes of sporadic clinical samples may show a
large diversity in epigenetic reprogramming during the
development of drug resistance. The high variability of
inter-individual epigenomic profiles poses a big chal-
lenge for the selection of useful epigenetic markers for
clinical practice.
Discussion
Chemotherapeutic agents triggering genotoxic stress
Irinotecan is activated by hydrolysis to SN38 which is a
topoisomerase I inhibitor [37]. Inhibition of topoisom-
erase I by SN38 can result in repression of both DNA
replication and transcription [37]. Oxaliplatin is a
platinum-based chemotherapeutic agent [38], which ex-
erts its effects by interfering with the DNA replication
and transcription machinery through nuclear DNA ad-
duct formation [39]. In the clinic, oxaliplatin’s efficacy
depends on combined use with 5-fluorouracil (5-FU)
[40]. Capecitabine is a prodrug, that is enzymatically
converted to 5-fluorouracil [41], which inhibits the
production of nucleotide thymidine by inhibiting the
enzyme thymidylate synthase [42]. These chemothera-
peutic agents are able to kill the bulk of cancer cells by
introducing stress. However, in some cases, stress also
can reactivate retrotransposition in somatic cells. For
instance, Hagan et al., reported that Alu retrotransposi-
tion can be induced by exposure to a variety of geno-
toxic stressors including the topoisomerase II inhibitor
Figure 6 The DNA methylation states (A) and the diversity of DNA methylation (entropy) (B) of the SOX1 gene for the 14 clinical samples.
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as hypoxia, contributing to the cancer phenotype in-
cluding drug resistance and genomic instability, can
increase transcription of SINEs (mainly Alu elements)
and LINEs by global demethylation [43]. Through the
analysis of RRBS data for the cell line models, we found
the enrichment of Alu sequences, especially the Alu Y
subfamily, in the SN38- and oxaliplatin-resistant cell
lines, which provides evidence of reactivation of Alu
retrotransposition during the development of drug re-
sistance in colorectal cancer cells. This finding sheds
light on the potential role of mobility of Alu elements in
colorectal cancer chemotherapeutic resistance by pre-
senting a genomic response to environmental stress.
At the molecular level, cancers are complex diseases
attributed to the accumulation of multiple risk factors,
from genetic predisposition to environmental factors
such as diet, lifestyle and exposure to toxic compounds
[44,45]. Epidemiological studies suggest that the envir-
onment influences cancer aetiology far more decisively
than genetics in many types of cancers [44,45]. DNA
methylation, as an important and long-term stable epi-
genetic mechanism, defines cell fate by maintaining gene
expression patterns and stabilizing genetic mobile ele-
ments. During development, germ line cells and embry-
onic stem cells show high cell fate dynamics and activity
of mobile genetic elements. Accordingly, DNA methyla-
tion also shows dynamic change. In somatic cells, cell
fate shows a stable differentiated state and mobile gen-
etic elements present in silent states, partly due to DNA
methylation locks. However, DNA methylation, as a
reversible chemical modification of DNA sequences can
also be changed according to environmental changes
involving endogenous or exogenous (bio)chemical mol-
ecules. DNA methylation changes could lead to instabil-
ity of cell fate and reactivation of retrotransposons. At
the cell level, somatic cells can become dedifferentiated
and heterogeneous, through reshuffling of the genome
and remodelling of the epigenome by reactivation of
retrotransposons. Through the analysis of DNA methy-
lomes from 421 individuals, ranging in age from 14 to
94 year old, Johansson et al., recently demonstrated that
aging at least affects DNA methylation of 29% of inves-
tigated sites, of which 60.5% are hypomethylated and
39.6% are hypermethylated [46]. Notably, they also
found that a higher fraction of sites in repetitive regions
is not affected by the process of aging [46]. This obser-
vation suggests that reactivation of Alu retrotransposi-
tion presented in our study is not a passive outcome of
aging but reflecting a response from mobile genetic ele-
ments to environmental stress in line with the finding
that the expression of Alu RNAs is shown to increase
in response to cellular stress, viral and translational
inhibition [8]. Of particular interest is that many priorobservations support a correlation between alterations
of DNA methylation of retrotransposons and colorectal
cancers [20,21,47,48].
Correlation between Alu retrotransposition and cell
stemness
An increasing body of evidence indicates that integra-
tion of L1 and Alu elements occurs in germ cells or
during early embryonic development [5]. Furthermore,
it is reported that the most expressed Alu elements are
enriched for the youngest subfamily Y in hESCs [49],
which is also in agreement with their recent evolution-
ary amplification in humans [8]. Additionally, non-CpG
methylation has been reported to occur in an asymmet-
ric, strand-specific manner in SINEs and LINEs in
hESCs and iPSCs, which is a characteristic property of
pluripotent cells [50].
The SOX1 and other SOX gene family members being
representative of stemness-related genes were identified
loci in set E. Furthermore, high diversity of DNA methy-
lation states of SOX1 and other SOX genes presented in
the clinical samples suggests that the cancer cells from
different patients are variably dedifferentiated. Notably,
SOX1, SOX2 and SOX3 compose the SOXB1 gene sub-
family, which shares more than 90% amino acid identity
with respect to the DNA binding high-mobility group
(HMG) box (a key characteristic sequence feature for
defining SOX gene family) and also a high degree of se-
quence similarity outside the HMG box [51]. Moreover,
SOX1 or SOX3 can substitute for SOX2 to produce iPS
cells [51]. The SOXB1 genes are frequently co-expressed
in development and exhibit high biological redundancy.
In our previous studies, SOX2 and other SOX gene
family members were implicated in the development of
resistance to the anti-cancer drug tamoxifen [52]. More-
over, the tamoxifen-resistant breast cancer cell lines
shared some common features with iPSCs (Li et al., in
preparation). By sequencing small cell lung cancers,
Rudin et al., reported that a considerable portion of
mutations occurring in SOX2 and other SOX genes indi-
cated a correlation between lung cancers and cell stem-
ness [53]. Our observations in the colorectal cancers and
in the tamoxifen-resistant breast cell line models ([52];
Li et al., in preparation) also suggest that the SOX gene
family might play an important role in tumorigenesis
and drug resistance.
Alu retrotransposition increases uncertainty for cancer
progression
In the present study, we initially hypothesized that de-
velopment of drug resistance in colorectal cancer
follows a linear step-wise progressive model. In this hy-
pothesis, we assume that all colorectal cancer cells
undergo a common path to develop drug resistance,
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alterations. Based on this hypothesis, we should be able
to use the selected ‘OxPt resistant phenotype-associated
methylation loci’ from the cell line models to predict
the outcome of response to oxaliplatin for the clinical
samples based on the information of DNA methylation
from the primary tumors. However, we could not find
such statistically significant predictors to precisely pre-
dict the outcome of treatment for the patients. An alter-
native hypothesis is that drug resistance may follow a
non-linear model, in which changes in genomes, epi-
genomes and cell fate could happen as part of the same
mechanism, i.e., retrotransposition, but individual patients
could show a diversity of reshaped genome and epige-
nome and high dynamics of cell fate states because of their
different initial conditions and potential stochastic events
during the development of drug resistance.
Alus act as endogenous genomic parasites using a
‘copy-and-paste’ mechanism to spread their copies to
new locations in the human genome, which can bring
three main biological consequences: reshuffling ge-
nomes, remodelling epigenomes and reprogramming cell
fates. All of these will contribute to heterogeneity of can-
cers, posing a big challenge for cancer therapy. A given
chemotherapy can kill many, even most, of the cancer
cells. On the other hand, cancer chemotherapy using
certain molecules targeting a given single target or path-
way might lose some of their effectiveness if the cancer
cells have acquired increased genetic diversity and chan-
ged cell fate. In the clinic, one failed therapeutic protocol
will be replaced by another one with new chemotherapeu-
tic agent(s). This strategy usually is effective at the begin-
ning, because a new environmental stress is introduced to
the cancer cells. However, retrotransposition might act as
a genomic response to environmental stress again and
eventually lead to resistance to the second treatment as
well. If a tumor can be detected at a very early phase, the
number of malignant cells is still limited. The probability
of development of fitness phenotypes by retrotransposi-
tion from the limited number of cells is lower than that
from large number of cells in a late phase tumor during
treatment. This non-linear model thus fits the clinical
notion that ‘earlier detection leads to better outcome’.
Additionally, this model also fits the McClintock doc-
trine, that increases in mobile genetic element tran-
scription that are caused by environmental stress lead
to higher levels of mobile genetic element integration
and these insertions have an impact on host phenotypes
and/or survival [5,33].
Conclusion
We have summarized the potential role of Alu ele-
ments in colorectal cancer chemotherapy resistance
in Figure 7. From this model, one can envision that asingle mechanism - reactivation of retrotransposition - will
bring an ‘unpredictable’ outcome. Because specificity of
target insertion of retrotransposons is weak and individual
host genomes and their modifications (epigenomes) are
different, spread of Alu copies in the genome will generate
a diversity of reshaped genomes and epigenomes. Somatic
retrotransposition as genomic response to environmental
stress occurs in a discernible but initially unforeseen de-
velopment [33]. Here, the two features of the non-linear
model are dependent on individual genomes and epigen-
omes (i.e., sensitive dependence of initial condition) and
initially in an unforeseen circumstance (i.e., dynamics and
evolution). These two features are two key characteristics
of complex systems. Therefore, system theory and meth-
odology, applied for interpreting complex systems might
be useful for cancer research. In clinical practice, sensitive
dependence of initial condition emphasizes the concept
of personalized medicine. Following the same simple
mechanism (retrotransposition), during tumor develop-
ment or acquiring resistance to cancer therapy, individ-
ual cancers could show different landscapes of genomes
and epigenomes. From intensive large scale cancer gen-
ome sequencing, even single types of cancers show high
diversity and it is quite hard to find individual muta-
tions that can commonly explain all cases. Some genetic
or epigenetic features, such as CIMP (CpG island meth-
ylator phenotype) [54,55], can match some subtypes of
cancers, but every cancer is unique. In addition to the
emphasis on individuality, dynamics are important
points to focus on in cancer therapy, because mobile
genetic elements are not simple genomic parasites but
they also contribute to fitness phenotypes of host ge-
nomes, fuelling evolution.
Consequently, our study underscores the uniqueness
of individual cancers, dynamic tracking of cancer pro-
gression and new therapy strategies targeting the entire
cell system.
Methods
SN38- and OxPt- resistant cell line models
Cell culture and generation of drug resistant cell lines
The cell lines HCT116 and HT29 were obtained from the
NCI/Development Therapeutics Program, while LoVo
was obtained from the American Tissue Culture Collec-
tion. Cells were maintained at 37°C, 5% CO2 in RPMI
1640 +Glutamax growth medium (Invitrogen, Naerum,
Denmark) supplemented with 10% foetal calf serum
(Invitrogen). Oxaliplatin or SN-38 resistant cell lines
were generated in our laboratory over a period of 8-10
months by continuous exposure to gradually increasing
concentrations of drug [30]. The cell lines were pas-
saged three times at each drug concentration and cell vials
were frozen at each increase in drug concentration. Prior
to subsequent experiments, the cells were maintained in
Figure 7 The potential role of Alu mobility in development of drug resistance in colorectal cancer cells. A typical model Alu element is
approximately 300 bp in length and has a dimeric structure. The elements are composed of two similar but not-equivalent monomers (7SL-derived left
monomer and 7SL-derived right monomer) joined by an A-rich linker. In the 7SL-derived left monomer, there are Box A and Box B, serving as
internal Pol III promoter elements, which are helped by an up-stream Pol III enhancer for efficient transcription. The right monomer is followed
by a short poly(A) tail and the both terminal sequences typically are Target Site Duplication (TSD) sequences (typically, AA\TTTT). In somatic
cells, Alu elements are silent. During tumorigenesis and cancer therapy, in response to the environmental stress induced by carcinogen(s) or
chemotherapeutic drug(s), the mobility of Alu elements is activated as a genomic response. Alus propagate using a ‘copy and paste’ mechanism. In
the ‘copy’ phase, Alus are typically transcribed by RNA polymerase III. For the ‘paste’ phase, Alus use a ribonucleoprotein complex composed of an
endonuclease and a reverse-transcriptase encoded by L1. The endonuclease initially cleaves one DNA strand, and the reverse-transcriptase copies an
Alu transcript into a single strand of DNA at that genomic location. The second DNA strand is cleaved by an unknown mechanism, and then the DNA
repair mechanism generates the strand complimentary to the novel Alu insertion. The process is named Target-Primed Reverse Transcription (TPRT).
Because of the two distinct single-strand breaks, the final DNA sequence contains a TSD, which is a sequence of 4 ~ 25 bp repeated just before and just
after the new Alu element.
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to establish the three drug resistant cell line models is pre-
sented in Additional file 8: Figure S3.
The cell line identity of parental and resistant cell lines
were confirmed using a short tandem repeat DNA analysis
(IdentiCell – Cell Line Authentication Service, Aarhus
University Hospital, Aarhus, Denmark). In addition, all cell
lines were confirmed to be mycoplasma-free (Mycoplasma
PCR Detection Kit, Minerva Biolabs, Berlin, Germany).
Chemotherapeutic drugs
Oxaliplatin (Eloxatin, 5 mg/ml, Sanofi-Aventis, Paris,
France) was stored at 4°C protected from light. SN-38
(Sigma-Aldrich, Copenhagen, Denmark) was dissolved indimethyl sulfoxide (DMSO) at a concentration of 10 mM
and stored at -20°C. Drugs were diluted in growth
medium immediately prior to use.
The clinical colorectal cancer samples
The timeline of the 14 patients under medical care
is shown in Additional file 9: Figure S4. Fresh frozen
tumor samples were obtained from a previously pub-
lished cohort [56], and were collected prior to any
chemotherapy. The clinicopathological information from
the 14 colorectal cancer patients has been displayed in
Additional file 10: Table S6. According to outcome of the
therapy (CR and PR versus NC and PD), the 14 patients
were divided into a ‘benefited’ and a ‘not benefited’ group
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the percentage of tumor cells were evaluated to account
for more than 70% (except MOMA5 and MOMA22
with 60% tumor cells) of the cells in each sample. The
genomic DNA was isolated from the samples and
passed the quality control for construction of RRBS
libraries. Written informed consent was obtained from
all patients and was approved by The Regional Ethics
Committee (DK: 1999/4678).
RRBS library generation and sequencing
RRBS was performed as previously described [52]. Briefly,
5 μg genome DNA from the cell line models and the clin-
ical samples was digested by restriction enzyme, MspI
(New England BioLabs) over night at 37°C and QIAGEN
Mini Purification kit was used to purify the digested prod-
ucts. End repair was performed, adding A and adaptors in
which the cytosines in the paired end adaptor sequence
were methylated. The ligated product was subjected to
size selection in 2% agarose gel (Bio-RAD) at 100 V for
2 hours. Agarose gel bands with the inserted genomic
DNA size 40 ~ 110 bp and the inserted genomic DNA size
110 ~ 220 bp were excised, so that two libraries were gen-
erated from each of the MOMA3, MOMA4, MOMA5,
MOMA7, MOMA8 and MOMA9 samples (one consisting
of 40 ~ 110 bp target sequences and the other of 110 ~
220 bp target sequences). The rest of the clinical
samples and all cell line samples were generated with a
single library with inserted DNA fragments of 40 ~
300 bp length. The DNA from the excised gel pieces
was recovered with the QIAGEN Gel Extraction Purifi-
cation Kit, followed by bisulfite treatment using ZYMO
EZ DNA Methylation-Gold kit. The resulting converted
DNA was amplified by PCR and purified. The RRBS
libraries were subjected to paired-end 50 nt sequencing
with HiSeq 2000 (Illumina).
Bioinformatic analysis
The adaptor sequences were filtered out before the sub-
sequent analysis and the resulting reads were aligned
using Bismark software [57]. Only uniquely mapped
reads, which had the restriction enzyme cutting site at
the 5’ end were used in the subsequent analysis. The se-
quencing depth and the percentages of methylated cyto-
sines/total investigated cytosines for each C location
were calculated. The genomic annotation information
was based on the hg19 human genome (http://geno-
me.ucsc.edu). Differentially methylated regions (DMRs)
were identified by quantitative differentially methylated
regions (QDMR) [31]. The QDMR is a quantitative
approach to quantify methylation difference and identify
DMRs from genome-wide methylation profiles with a
concept of ‘DNA methylation entropy’ [31]. The ‘DNA
methylation entropy’ adapting Shannon entropy wasused to estimate diversity (or variety) of DNA methylation
states for a given locus across samples [31]. We applied
WebLogo 3.3 [34] to extract the flanking sequence (up-
and down- stream 20 bp) motifs for the investigated
genomic sequences. We applied GeneCluster 2.0 [36] to
perform the supervised cluster analysis and prediction
analysis.
Availability of supporting data
The data set supporting the results of this article is avail-
able in the NCBI Gene Expression Omnibus database
accession number (for the raw data and metadata of
RRBS for the three colorectal cancer drug-resistant cell
line models and the 14 sporadic clinical colorectal can-
cer samples) is GSE56269. http://www.ncbi.nlm.nih.gov/
gds/?term=GSE56269.
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Additional file 1: Figure S1. Methylome profiles of the colorectal
cancer cell line models and the clinical colorectal cancer samples.
Unsupervised clustering profiles of differentially methylated cytosines
(DMCs) in the RRBS data for the three colorectal cancer cell line models
and the clinical 14 colorectal cancer patients in the context of CpG
(Supplementary Fig. 1A), CHG (Supplementary Fig. 1B), and CHH
(Supplementary Fig. 1C). The DNA methylation level is shown as
percentage. Full green color means 100 percent DNA methylation,
whereas full red color means 0 percent DNA methylation. The
intermediate DNA methylation levels are shown in gradient color
between full green and full red according to the DNA methylation
level (percentage).
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